|
1
|
Campbell LL and Polyak K: Breast tumor
heterogeneity: Cancer stem cells or clonal evolution? Cell Cycle.
6:2332–2338. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cancer Genome Atlas Network, .
Comprehensive molecular portraits of human breast tumours. Nature.
490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bitterman A, Kessner R, Goldman I, Shiloni
E and Steiner M: Intraoperative radiotherapy for breast cancer. Isr
Med Assoc J. 14:256–259. 2012.PubMed/NCBI
|
|
4
|
Murawa P, Murawa D, Adamczyk B and Połom
K: Breast cancer: Actual methods of treatment and future trends.
Rep Pract Oncol Radiother. 19:165–172. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Williams NR, Pigott KH and Keshtgar MR:
Intraoperative radiotherapy in the treatment of breast cancer: A
review of the evidence. Int J Breast Cancer. 2011:3751702011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sedlmayer F, Reitsamer R, Fussl C, Ziegler
I, Zehentmayr F, Deutschmann H, Kopp P and Fastner G: Boost IORT in
breast cancer: Body of evidence. Int J Breast Cancer.
2014:4725162014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liberman L, Van Zee KJ, Dershaw DD, Morris
EA, Abramson AF and Samli B: Mammographic features of local
recurrence in women who have undergone breast-conserving therapy
for ductal carcinoma in situ. AJR Am J Roentgenol. 168:489–493.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fisher B, Dignam J, Wolmark N, Mamounas E,
Costantino J, Poller W, Fisher ER, Wickerham DL, Deutsch M,
Margolese R, et al: Lumpectomy and radiation therapy for the
treatment of intraductal breast cancer: Findings from national
surgical adjuvant breast and bowel project B-17. J Clin Oncol.
16:441–452. 1998.PubMed/NCBI
|
|
9
|
Fastner G, Sedlmayer F, Merz F,
Deutschmann H, Reitsamer R, Menzel C, Stierle C, Farmini A, Fischer
T, Ciabattoni A, et al: IORT with electrons as boost strategy
during breast conserving therapy in limited stage breast cancer:
Long term results of an ISIORT pooled analysis. Radiother Oncol.
108:279–286. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Demicheli R, Valagussa P and Bonadonna G:
Does surgery modify growth kinetics of breast cancer
micrometastases? Br J Cancer. 85:490–492. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Baum M, Demicheli R, Hurshesky W and
Retsky M: Does surgery unfavorable perturb the ‘natural history’ of
early breast cancer by accelerating the appearance of distant
metastases? Eur J Cancer. 41:508–515. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fisher B, Gunduz N, Coyle J, Rudock C and
Saffer E: Presence of growth-stimulating factor in serum following
primary tumor removal in mice. Cancer Res. 49:1996–2001.
1989.PubMed/NCBI
|
|
13
|
Tsuchida Y, Sawada S, Yoshioka I, Ohashi
Y, Matsuo M, Harimaya Y, Tsukada K and Saiki I: Increased surgical
stress promotes tumor metastasis. Surgery. 133:547–555. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ménard S, Balsari A, Casalini P, Tagliabue
E, Campiglio M, Bufalino R and Cascinelli N: HER-2 positive breast
carcinomas as a particular subset with peculiar clinical behaviors.
Clin Canc Res. 8:520–525. 2002.
|
|
15
|
Tagliabue E, Agresti R, Carcangiu ML,
Ghirelli C, Morelli D, Campiglio M, Martel M, Giovanazzi R, Greco
M, Balsari A and Ménard S: Role of HER2 in wound-induced breast
carcinoma proliferation. Lancet. 362:527–533. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Belletti B, Vaidya JS, D'Andrea S,
Entschladen F, Roncadin M, Lovat F, Berton S, Perin T, Candiani E,
Reccanello S, et al: Targeted intraoperative radiotherapy impairs
the stimulation of breast cancer cell proliferation and invasion
caused by surgical wounding. Clin Cancer Res. 14:1325–1332. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dalerba P, Cho RW and Clarke MF: Cancer
stem cells: Models and concepts. Annu Rev Med. 58:267–284. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Visvader JE and Lindeman GJ: Cancer stem
cells in solid tumors: Accumulating evidence and unresolved
questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dean M, Fojo T and Bates S: Tumor stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Brunner TB, Kunz-Schughart LA,
Grosse-Gehling P and Baumann M: Cancer stem cells as a predictive
factor in radiotherapy. Semin Radiat Oncol. 22:151–174. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bapat SA, Mali AM, Koppikar CB and Kurrey
NK: Stem and progenitor-like cells contribute to the aggressive
behavior of human epithelial ovarian cancer. Cancer Res.
65:3025–3029. 2005.PubMed/NCBI
|
|
22
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Abraham BK, Fritz P, McClellan M,
Hauptvogel P, Athelogou M and Brauch H: Prevalence of
CD44+/CD24−/low cells in breast cancer may
not be associated with clinical outcome but may favor distant
metastasis. Clin Cancer Res. 11:1154–1159. 2005.PubMed/NCBI
|
|
24
|
Ginestier C, Hur MH, Charafe-Jauffret E,
Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG,
Liu S, et al: ALDH is a marker of normal and malignant human
mammary stem cells and a predictor of poor clinical outcome. Cell
Stem Cell. 1:555–567. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tanei T, Morimoto K, Shimazu K, Kim SJ,
Tanji Y, Taguchi T, Tamaki Y and Noguchi S: Association of breast
cancer stem cells identified by aldehyde dehydrogenase 1 expression
with resistance to sequential paclitaxel and epirubicin-based
chemotherapy for breast cancers. Clin Cancer Res. 15:4234–4241.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Croker AK, Goodale D, Chu J, Postenka C,
Hedley BD, Hess DA and Allan AL: High aldehyde dehydrogenase and
expression of cancer stem cell markers selects for breast cancer
cells with enhanced malignant and metastatic ability. J Cell Mol
Med. 13:2236–2252. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Marcato P, Dean CA, Giacomantonio CA and
Lee PW: Aldehyde dehydrogenase: Its role as a cancer stem cell
marker comes down to the specific isoform. Cell Cycle.
10:1378–1384. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Park SY, Lee HE, Li H, Shipitsin M, Gelman
R and Polyak K: Heterogeneity of stem-cell related markers
according to tumor subtype and histologic stage in breast cancer.
Clin Cancer Res. 16:876–887. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bromberg JF, Wrzeszczynska MH, Devgan G,
Zhao Y, Pestell RG, Albanese C and Darnell JE Jr: STAT3 as an
oncogene. Cell. 98:295–303. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lin L, Hutzen B, Lee HF, Peng Z, Wang W,
Zhao C, Lin HJ, Sun D, Li PK, Li C, et al: Evaluation of STAT3
signaling in ALDH+ and
ALDH+/CD44+/CD24− subpopulations
of breast cancer cells. PLoS One. 8:e828212013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Holliday DL and Speirs V: Choosing the
right cell line for breast cancer research. Breast Cancer Res.
13:2152011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Neve RM, Chin K, Fridlyand J, Yeh J,
Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al: A
collection of breast cancer cell lines for the study of
functionally distinct cancer subtypes. Cancer Cell. 10:515–527.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Demicheli R, Retsky MW, Hrushesky WJ and
Baum M: Tumor dormancy and surgery-driven interruption of dormancy
in breast cancer: Learning from failures. Nat Clin Pract Oncol.
4:699–710. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Marches R, Scheuermann R and Uhr J: Cancer
dormancy: From mice to man. Cell Cycle. 5:1772–1778. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Arnold KM, Opdenaker LM, Flynn D and
Sims-Mourtada J: Wound healing and cancer stem cells: Inflammation
as a driver of treatment resistance in breast cancer. Cancer Growth
Metastasis. 8:1–13. 2015.PubMed/NCBI
|
|
36
|
Fisher B, Gunduz N and Saffer EA:
Influence of the interval between primary tumor removal and
chemotherapy on kinetics and growth of metastases. Cancer Res.
43:1488–1492. 1983.PubMed/NCBI
|
|
37
|
Segatto I, Berton S, Sonego M, Massarut S,
Perin T, Piccoli E, Colombatti A, Vecchione A, Baldassarre G and
Belletti B: Surgery-induced wound response promotes stem-like and
tumor-initiating features of breast cancer cells, via STAT3
signaling. Oncotarget. 5:6267–6279. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ma F, Li H, Wang H, Shi X, Fan Y, Ding X,
Lin C, Zhan Q, Qian H and Xu B: Enriched CD44(+)/CD24(−) population
drives the aggressive phenotypes presented in triple-negative
breast cancer (TNBC). Cancer Lett. 353:153–159. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Camerlingo R, Ferraro GA, De Francesco F,
Romano M, Nicoletti G, Di Bonito M, Rinaldo M, D'Andrea F and
Pirozzi G: The role of CD44+/CD24−/low
biomarker for screening, diagnosis and monitoring of breast cancer.
Oncol Rep. 31:1127–1132. 2014.PubMed/NCBI
|
|
40
|
Shipitsin M, Campbell LL, Argani P,
Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T,
Serebryiskaya T, Beroukhim R, Hu M, et al: Molecular definition of
breast tumor heterogeneity. Cancer Cell. 11:259–273. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sheridan C, Kishimoto H, Fuchs RK,
Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R Jr, Badve S and
Nakshatri H: CD44+/CD24− breast cancer cells
exhibit enhanced invasive properties: An early step necessary for
metastasis. Breast Cancer Res. 8:R592006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Idowu MO, Kmieciak M, Dumur C, Burton RS,
Grimes MM, Powers CN and Manjili MH: CD44(+)/CD24(−/low) cancer
stem/progenitor cells are more abundant in triple-negative invasive
breast carcinoma phenotype and are associated with poor outcome.
Hum Pathol. 43:364–373. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ahmed MA, Aleskandarany MA, Rakha EA,
Moustafa RZ, Benhasouna A, Nolan C, Green AR, Ilyas M and Ellis IO:
A CD44−/CD24+ phenotype is a poor prognostic
marker in early invasive breast cancer. Breast Cancer Res Treat.
133:979–995. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Meyer MJ, Fleming JM, Ali MA, Pesesky MW,
Ginsburg E and Vonderhaar BK: Dynamic regulation of CD24 and the
invasive, CD44posCD24neg phenotype in breast cancer cell lines.
Breast Cancer Res. 11:R822009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhong Y, Lin Y, Shen S, Zhou Y, Mao F,
Guan J and Sun Q: Expression of ALDH1 in breast invasive ductal
carcinoma: An independent predictor of early tumor relapse. Cancer
Cell Int. 13:602013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Vaidya JS, Wenz F, Max Bulsara M, Tobias
JS, Joseph DJ, Keshtgar M, Flyger HL, Massarut S, Alvarado M,
Saunders C, et al: Risk-adapted targeted intraoperative
radiotherapy versus whole-breast radiotherapy for breast cancer:
5-year results for local control and overall survival from the
TARGIT-A randomised trial. Lancet. 383:603–613. 2014. View Article : Google Scholar : PubMed/NCBI
|
